Fresenius Medical Care Appoints Dr. Amaka Eneanya as Head of Strategy and Operations for the Company’s Global Medical Office

Dr. Eneanya was previously a tenured nephrologist and assistant professor of medicine and epidemiology at University of Pennsylvania, where she served as Director of Health Equity, Anti-Racism and Community Engagement in the Division of Nephrology. At Fresenius Medical Care, she will report directly to the Global Medical Director and will be part of the Global Medical Office leadership team.

“As a board-certified clinician and expert researcher, Dr. Eneanya brings a wealth of knowledge and expertise that will advance our work in improving outcomes for people living with kidney disease,” said declared Frank Maddux, MD, Global Medical Director of Fresenius Medical Care. “His insights into health equity, patient-reported outcomes, and social engagement in healthcare and public health will be key to informing our ongoing medical strategy.”

Dr. Eneanya is the co-author of a widely cited paper that argues that when estimating glomerular filtration rate (eGFR) equations, it is problematic to assert that organ function differs between individuals whose physical conditions are essentially identical except for their race. Published in the prestigious Journal of the American Medical Association in 2020, the articleas well as the vast scientific knowledge of Dr. Eneanya advocacyhelped spark a national conversation in the United States about removing race from the kidney function algorithm.

The American Society of Nephrology and the National Kidney Foundation then established a joint task force to re-evaluate the inclusion of race in eGFR and its implications for the diagnosis and management of patients with kidney failure. The working group, on which Dr. Eneanya sat, recently recommended the immediate adoption of a new race-free eGFR equation.

Dr. Eneanya’s research has been supported by the National Institutes of Health and the American Society of Nephrology. She has received numerous honors including the Radhika Srinivasan Award for Humanism and Professionalism in Medicine of the University of Pennsylvania Last year. In 2020, she was recognized as a “40 under 40 Leader in Minority Health” by the National Minority Quality Forum.

A Fellow of the American Society of Nephrology, Dr. Eneanya completed her internal medicine residency at Brigham and Women’s Hospital in Boston and nephrology training through the combined Massachusetts General Hospital/Brigham and Women’s Hospital Nephrology Fellowship Program. She holds an undergraduate degree from Cornell Universitya medical degree from Meharry Medical Collegeand a Masters in Public Health from the Harvard TH Chan School of Public Health.

Fresenius Medical Care is the world’s leading provider of products and services for people with kidney disease, of whom approximately 3.8 million patients worldwide regularly undergo dialysis treatment.

Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatment to approximately 345,000 patients worldwide. Fresenius Medical Care is also the main supplier of dialysis products such as dialysis machines or dialyzers. Along with its core business, the renal care continuum, the Company is focused on expanding into complementary areas and into the area of ​​critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).

For more information, visit the company’s website at www.freseniusmedicalcare.com.

Media Contact:
Brad Puffer
Phone. 781-699-3331
[email protected]

SOURCE Fresenius Medical Care Holdings, Inc.